Product NDC: | 0008-1211 |
Proprietary Name: | Pristiq |
Non Proprietary Name: | DESVENLAFAXINE SUCCINATE |
Active Ingredient(s): | 50 mg/1 & nbsp; DESVENLAFAXINE SUCCINATE |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET, EXTENDED RELEASE |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0008-1211 |
Labeler Name: | Wyeth Pharmaceuticals Company, a subsidiary of Pfizer Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | NDA021992 |
Marketing Category: | NDA |
Start Marketing Date: | 20080501 |
Package NDC: | 0008-1211-14 |
Package Description: | 14 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0008-1211-14) |
NDC Code | 0008-1211-14 |
Proprietary Name | Pristiq |
Package Description | 14 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0008-1211-14) |
Product NDC | 0008-1211 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | DESVENLAFAXINE SUCCINATE |
Dosage Form Name | TABLET, EXTENDED RELEASE |
Route Name | ORAL |
Start Marketing Date | 20080501 |
Marketing Category Name | NDA |
Labeler Name | Wyeth Pharmaceuticals Company, a subsidiary of Pfizer Inc. |
Substance Name | DESVENLAFAXINE SUCCINATE |
Strength Number | 50 |
Strength Unit | mg/1 |
Pharmaceutical Classes | Norepinephrine Uptake Inhibitors [MoA],Serotonin and Norepinephrine Reuptake Inhibitor [EPC],Serotonin Uptake Inhibitors [MoA] |